Objective-To investigate whether soluble interleukin-2 receptor (sIL-2R) could be a useful marker of disease activity in rheumatoid arthritis (RA); sIL-2R levels in serum and in synovial fluid were determined by enzyme-linked immunosorbent assay. Methods-Sixty five serum and 27 synovial fluid samples were obtained from patients with RA. Twenty five serum and 28 synovial fluid samples from patients with osteoarthritis (OA) were used as controls. Furthermore, 10 synovial fluid samples from healthy volunteers were also examined. Variable laboratory and clinical data were compared with serum sIL-2R levels, in 26 patients with RA and serial samples from some patients were examined. Results-Concentrations of sIL-2R in serum (median 81, range 40-350 pM) and synovial fluid (median 125, range 52-460 pM) from patients with RA were significantly higher than in serum (median 45, range 13-100 pM) and synovial fluid (median 37, range 15-140 pM) from patients with OA, and healthy control synovial fluid (median 2 5, range 0-10 pM). Serum sIL-2R levels correlated strongly with serum levels of C-reactive protein (p = 0.0001), and a significant correlation with erythrocyte sedimentation rate (ESR) (p = 0.048), IgG levels (p = 0.028), IgA levels (p = 0.044) and Lansbury Index (p = 0.037) was observed. However, serum sIL-2R levels showed no significant correlation with rheumatic factor, IgM or T cell subsets. Conclusion-These findings indicate that sIL-2R levels in patients with RA reflect disease activity.
Abstract
Objective-To investigate whether soluble interleukin-2 receptor (sIL-2R) could be a useful marker of disease activity in rheumatoid arthritis (RA); sIL-2R levels in serum and in synovial fluid were determined by enzyme-linked immunosorbent assay. Methods-Sixty five serum and 27 synovial fluid samples were obtained from patients with RA. Twenty five serum and 28 synovial fluid samples from patients with osteoarthritis (OA) were used as controls. Furthermore, 10 synovial fluid samples from healthy volunteers were also examined. Variable laboratory and clinical data were compared with serum sIL-2R levels, in 26 patients with RA and serial samples from some patients were examined. Results-Concentrations of sIL-2R in serum (median 81, range 40-350 pM) and synovial fluid (median 125, range 52-460 pM) from patients with RA were significantly higher than in serum (median 45, range 13-100 pM) and synovial fluid (median 37, range pM) from patients with OA, and healthy control synovial fluid (median 2 5 , range 0-10 pM). Serum sIL-2R levels correlated strongly with serum levels of C-reactive protein (p = 0.0001), and a significant correlation with erythrocyte sedimen- 16 19 20 However, controversy exists on whether elevated levels of sIL-2R in the serum of RA patients reflects disease activity,'5 as several studies on sIL-2R regulation have demonstrated. 2' 22 In this study we measured the sIL-2R levels in serum and synovial fluid ofpatients with RA, and determined whether they correlated with clinical and laboratory parameters of disease activity. Materials 10 healthy volunteers (7 men and 3 women).
CLINICAL EVALUATION
A number of clinical variables were examined in each patient. The erythrocyte sedimentation rate (ESR) was determined by the Westergren method. C-reactive protein (CRP) was quantified by a turbidometric method. Rheumatoid factor (RF) was measured by nepherometry and rheumatoid arthritis haemagglutinin (RAHA) was measured by microtitre methods. Serum immunoglobulin levels were determined by nepherometry. CD8 (%) Figure 4 Correlations between serum levels ofsoluble interleukin-2 receptor (sIL-2R) and CD4 and CD8 T cell subsets in patients with rheumatoid arthritis. No statistically significant correlation was found. significant. Regression analysis and correlations were also performed using the same programme.
Results Figure 1 shows that serum sIL-2R levels were considerably elevated in patients with RA CRP (mg/di) Figure 7 Correlation between serum levels of soluble interleukin-2 receptor (sIL-2R) and C-reactive protein (CRP) in patients with rheumatoid arthritis. A statistically significant correlation was found (r = 0 -76, p = 0 -0001).
(median 81, range 40-350 pM) compared with the levels in OA patients (median 45, range 13-100 pM) (p <OOOOl). Figure 2 shows that sIL-2R levels in the synovial fluid of patients with RA (median 125, range 52-460 pM) were significantly higher than in OA patients (median 37, range 15-140 pM) and in healthy controls (median 2-5, range 0-10 pM) (p < 0-000 1).
We also examined relationships between serum sIL-2R levels and clinical and laboratory parameters. There was no correlation between serum sIL-2R and either RF or RAHA (fig 3) .
The relative percentages of CD4 and CD8 cells in the T cell subsets showed no significant correlations with sIL-2R levels (fig 4) . IgG (r =0-504, p = 0-027) and IgA (r = 0-463, p =0-043) levels correlated significantly with serum sIL-2R levels, however, IgM did not ( fig  5) . Although ESR showed only a weak correlation with sIL-2R levels (r = 0-4 17, p = 0-048), CRP correlated strongly (r=0753, p=0-0001) (fig 6 and 7) . The Lansbury index also exhibited a positive correlation with serum sIL-2R levels (r = 0-47, p = 0-037) (fig 8) .
Serum sIL-2R levels and CRP levels were determined from three patients with RA at different times during the course of their treatment. sIL-2R values decreased along with a concomitant decrease in CRP levels (data not shown). that synovial fluid levels of sCD4 correlated positively with sIL-2R levels but no correlation with sCD8 levels was observed. Thus T cell subsets in peripheral blood do not reflect the T cell subsets at the site of inflammation, so examination of T cell subsets in the synovial fluid would provide more accurate information on the relationship with sIL-R levels.
In conclusion, measurement of sIL-2R levels in serum and synovial fluid of patients with RA was useful in assessing disease activity.
